

**YMTHE, Volume 25**


## **Supplemental Information**

### **Gene Therapy Restores Balance and Auditory**

### **Functions in a Mouse Model of Usher Syndrome**

**Kevin Isgrig, Jack W. Shteamer, Inna A. Belyantseva, Meghan C. Drummond, Tracy S. Fitzgerald, Sarath Vijayakumar, Sherri M. Jones, Andrew J. Griffith, Thomas B. Friedman, Lisa L. Cunningham, and Wade W. Chien**

1



2

3 **Supplementary Figure 1: AAV8-whirlin gene therapy delivered through the**  
4 **posterior semicircular canal successfully perfused all vestibular end-organs.**


5 Whirlin expression (green) is seen at the stereocilia tips of hair cells from all five  
6 vestibular end-organs (utricle, saccule, superior/horizontal/posterior semicircular  
7 canals). All images were taken at P120 from the same whirler mouse that received  
8 AAV8-whirlin gene therapy.

9

10

11

12



13

14 **Supplementary Figure 2: AAV8-GFP injection into the whirler posterior**  
15 **semicircular canal had no effect on stereocilia length.** When the negative control  
16 virus AAV8-GFP was injected into the whirler posterior semicircular canal, GFP  
17 expression was seen in both infected hair cells and supporting cells throughout the  
18 utricle (a). However, stereocilia bundles (white) remained abnormally short (b-f).


19

20

21

22

23



25

26 **Supplementary Figure 3: VsEP measurements in whirlers that underwent AAV8-**  
 27 **whirlin injections. (a)** All whirler mice that received unilateral and bilateral AAV8-  
 28 whirlin gene therapy had measurable VsEP thresholds. One of 9 whirler controls that  
 29 did not receive AAV8-whirlin gene therapy had absent VsEP threshold (a threshold of  
 30 10 dB indicates a lack of measurable threshold). **(b)** Normal control littermates showed  
 31 a steady increase in P1-N1 amplitude with increasing stimulus levels. This stimulus-  
 32 level-dependent P1-N1 amplitude was also seen in whirlers that received bilateral  
 33 AAV8-whirlin gene therapy, and was absent in whirler controls. **(c)** Whirlers that

34 received bilateral AAV8-whirlin gene therapy had significant improvement in VsEP P1  
35 latency compared to untreated whirler controls.

36

37

38

39

40

41

42

43

44

45

46

47


48

49

50

51


52



53

54 **Supplementary Figure 4: AAV8-GFP injected through the posterior semicircular**  
55 **canal infected both IHCs and OHCs in the cochlea.** Low (a) and high (b)  
56 magnification images of the cochlear middle turn from a neonatal whirler mouse that  
57 underwent AAV8-GFP injections into the posterior semicircular canal. AAV8-GFP  
58 efficiently infected both inner and outer hair cells.

59



60

61 **Supplementary Figure 5: AAV8-whirlin gene therapy infected both IHCs and OHCs**

62 **in the cochlea.** (a) Middle turn of the cochlea of a P30 whirler mouse that received

63 AAV8-whirlin gene therapy. There is robust AAV8-whirlin infection (green) in all IHCs,

64 as well as some OHCs (white arrows). (b) Apical turn of the cochlea of a P120 whirler

65 mouse that received AAV8-whirlin gene therapy. While some outer hair cells were


66 infected and expressed whirlin at the stereocilia tips (white arrows), most outer hair cells

67 were not infected (white arrowheads).

68

69

70



71

72

73 **Supplementary Figure 6: Comparison of ABR thresholds at P30 and P120 in**

74 **whirler mice that received AAV8-whirlin gene therapy.** Two out of seven mice had

75 measurable ABR thresholds at P120 (at 8 and 32 kHz). The average ABR threshold

76 data from P30 are shown for comparison (black dashed line).

77

78

79

80